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Letters to the EditorIs HCV RNA analysis at day 7 cost-effective in deciding the duration
of therapy in chronic HCV genotype 2/3 infection?To the Editor:
The recent study by Sarrazin et al. [1] reported results from a re-
analysis of stored sera from two large multicenter randomized
trials [2,3], in HCV infected patients treated with peginterferon
alfa-2a plus ribavirin. The authors quantiﬁed HCV RNA using
COBAS Ampliprep/COBAS TaqMan (CAP–CTM), a sensitive real-
time PCR-based assay with a limit of detection of 615 IU/ml.
Among genotype 2/3 infected patients achieving a rapid virologic
response (RVR; deﬁned as HCV RNA <15 IU/ml after 4 weeks of
therapy), a sustained viral response (SVR) rate of 83% was noted
for patients treated for 16 weeks and 91% for those treated for
24 weeks. These SVR rates were observed in both study arms
even when using a stricter deﬁnition of undetectable HCV RNA
(CAP–CTM). However, when the analysis was limited to patients
with a baseline viral load below 800,000 IU/ml, i.e. a third of the
patients included, the authors found no statistically signiﬁcant
difference in SVR rates between patients treated for 16 or 24-
weeks irrespective of the cut-off used to deﬁne RVR.
In another recently reported trial with HCV genotype 2/3
infected patients (NORDynamIC; n = 382) treated with peginter-
feron alfa-2a weekly plus 800 mg ribavirin daily for 12 orJournal of Hepatology 2
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Fig. 1. Histogram displaying the percentage of patients in the intention-to-treat ana
level on day 29 among patients with a low baseline viral load, i.e. below 800,000 IU/ml o
Values calculated using Chi squared.24 weeks, plasma samples were analyzed using the CAP–CTM
assay [4]. It was observed that 12 weeks of treatment overall
was signiﬁcantly inferior to 24 weeks, but that short-term
therapy may be acceptable for patients younger than 40 years
of age [4] as well as for those achieving HCV RNA below
1000 IU/ml by day 7, i.e. immediately prior to the second dose
of peginterferon [5].
The analysis of the 136 patients in this trial with baseline viral
load below 800,000 IU/ml and a plasma sample available day 29,
according to the proposal by Sarrazin et al., revealed a non-
signiﬁcant trend towards slightly higher SVR among patients
with HCV RNA <15 IU/ml day 29 treated for 24 weeks (Fig. 1A;
p = 0.08, Chi square) whereas no such trend was seen among
109 patients achieving below 1000 IU/ml day 7 irrespective of
their baseline viral load (Fig. 1B). In contrast, among patients
with HCV RNA levels above or equal to 1000 IU/ml day 7, SVR
rates were signiﬁcantly higher in the 24-week study arm irre-
spective of whether RVR (i.e. <15 IU/ml HCV RNA day 29) was
achieved or not (55% vs. 87%, p = 0.0002, and 39% vs. 62%,
p = 0.01, Chi squared; Fig. 1B). These results imply that a single
day 7 analysis of HCV RNA is at least as accurate as an assessment011 vol. 54 j 835–839
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Letters to the Editor
of RVR in deciding whether genotype 2/3-infected patients
should receive short-term treatment. Additionally, considering
that sampling HCV RNA on day 7 entails only one sampling
instead of the two suggested by Sarrazin et al., i.e. baseline and
week 4, while identifying approximately as many suitable candi-
dates for short-term therapy, sampling at day 7 is likely to be
more cost-effective for patients infected with HCV genotype 2
or 3. Also, the suggested cut-off level of 1000 IU/ml is stably
quantiﬁable by most currently available assays, and is not prone
to re-deﬁnition as the limits of detection of HCV RNA analyses
will further improve over time. Similarly, since it is important
that the day 7 HCV RNA sample is drawn immediately prior to
the second dose of pegylated interferon, this allows for an
additional opportunity to directly observe the patient’s injection
technique as well as minimize the risk of sampling variations in
relation to the previous dose as is often the case with week 4
HCV RNA determination. However, it is important to consider
the intra- and inter-assay variability of real-time PCR based HCV
RNA assays [6] as well as differences between methods that
persist despite the introduction of WHO standardizations [7],
which obviously affect all proposed algorithms based on quantita-
tive HCV RNA determinations, including those at baseline or day 7.
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For the NORDynamIC Study GroupViral kinetics for individualized treatment durationsReply to Lagging et al.:
The shortening of treatment duration is the most important aim
for improving antiviral therapy in patients with chronic hepatitis
C. The new direct antiviral agents currently in development
should allow an increasing number of patients to beneﬁt from
shortened treatment durations and consequently to signiﬁcantly
increase the number of patients who are willing and able to
receive antiviral therapy. Algorithms for abbreviated treatment
durations established for the current standard of care are mainly
based on viral kinetics. In addition, while not visible in smaller
studies [1,2] all large studies have shown that in patients with
high baseline viral load, higher relapse rates were observed,
although they become HCV RNA negative at time points thatare identical to those reported in patients with a low baseline
viral load [3,4]. Thus, in the NORDynamIC study reported by Lag-
ging et al., baseline viral load may not be a signiﬁcant predictor of
relapse in patients with virologic response at day 7 because of the
limited number of patients investigated [5]. However, it may also
be that the selection of patients for shortened treatment very
early on during therapy (i.e. day 7) and the application of a viral
cut-off level (i.e. 1000 IU/ml) rather than undetectable HCV RNA,
allow for a response to be predicted independent of baseline viral
load. This has to be explored in future studies. However, while
the assessment of virologic response very early during therapy
may indeed have the potential of very high positive predictive
values of sustained virologic response, the number of patients011 vol. 54 j 835–839
